Nanodropper Now Operating as Mu Medical Under New Consolidation Plan
Nanodropper, provider of micro-volume ophthalmic delivery technology, announced that Bedo Solutions and Viseon Labs have agreed on terms to join its eyecare platform under a new corporate identity, Mu Medical. Financial terms of the deal were not disclosed.
Nanodropper said the planned consolidation represents an expansion, transforming the company from a single-product device manufacturer into a broader, commercial-stage medtech ecosystem spanning hardware, software, and data-driven therapeutics.
Upon closing, Mu Medical will integrate assets and intellectual property from Bedo Solutions and Viseon Labs with Nanodropper’s existing infrastructure. The combined platform is designed to address the full lifecycle of ocular care—from how therapies are delivered to how treatment is monitored and personalized over time.
“Eyecare has historically been treated as a one-size-fits-all model, from standardized drop sizes to static treatment plans,” said Allisa Song, MD, Founder and CEO of Nanodropper. “We are building Mu Medical to break that mold. By bringing Bedo Solutions and Viseon Labs into our ecosystem, we will be able to personalize the entire journey: from delivering the precise dose a patient needs to monitoring adherence at home and using AI to tailor therapy in real time.”
Mu Medical will organize its portfolio around four complementary product verticals designed to advance precision and personalized eyecare:
Consumer Devices: Nanodropper Adaptor and GentleDrop support patient-centered use of existing ophthalmic therapies
Primary Packaging: MuPACK-JT2, MuVEYE, and MuMIST incorporate proprietary micro-volume delivery technologies to enable precision dosing at the source
Monitoring and Oculomics: VuTRACK uses machine vision to track adherence and generate actionable health insights
AI Therapeutics: Myopia AI and VizGuard apply advanced analytics to support personalized, AI-driven treatment decisions
Following closing, the leadership structure of Mu Medical is expected to include:
Allisa Song, MD, Founder and CEO of Nanodropper, serving as Chief Executive Officer and Board Chair
Sina Fateh, MD, Founder and CEO of Viseon Labs, serving as Chief Strategy Officer and Board Observer
Robert Kinast, MD, Founder and CEO of Bedo Solutions, serving as Board Observer and Medical Advisor
Industry Debut During JPM Healthcare Week
Mu Medical will be formally introduced to the healthcare and investment community during the 44th Annual J.P. Morgan Healthcare Conference week, taking place January 12–15, 2026, in San Francisco. Dr. Song and Dr. Fateh are scheduled to present the company’s vision during the week.
In conjunction with the announcement, Viseon Labs has been selected as a presenting company at the MIT Innovation Showcase & Reception, where the leadership team will outline the Mu Medical strategy to investors and medtech leaders.
Originally published online on Eyewire+.